The pleiotropic effects of statins and omega-3 fatty acids against sepsis: a new perspective

Bibliography

• Padkin A, Goldfrad C, Brady AR, Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland. Crit Care Med 2003;19:2332-8
   Google Scholar
• Anderson RN, Smith BL. Deaths: leading causes for 2001. Natl Vital Stat Rep 2003;52:1-85
   Google Scholar
• Weycker D, Akhras KS, Edelsberg J, Long-term mortality and medical care charges in patients with severe sepsis. Crit Care Med 2003;31:2316-23
   PubMed Web of Science ®Google Scholar
• Angus D, Linde-Zwirble W, Lidicker J, Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-10
   PubMed Web of Science ®Google Scholar
• Marshall JC. Sepsis: current status, future prospects. Curr Opin Crit Care 2004;10:250-64
   PubMedGoogle Scholar
• Tleyjeh IM, Kashour T, Hakim FA, Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med 2009;169:1658-67
   PubMed Web of Science ®Google Scholar
• Kopterides P, Falagas ME. Statins for sepsis: a critical and updated review. Clin Microbiol Infect 2009;15:325-34
   PubMed Web of Science ®Google Scholar
• Falagas ME, Makris GC, Matthaiou DK, Rafailidis PI. Statins for infection and sepsis: a systematic review of the clinical evidence. J Antimicrob Chemother 2008;61:774-85
   PubMed Web of Science ®Google Scholar
• Marik PE, Zaloga GP. Immunonutrition in critically ill patients: a systematic review and analysis of the literature. Intensive Care Med 2008;34:1980-90
   PubMed Web of Science ®Google Scholar
• Berger MM, Chioléro RL. Antioxidant supplementation in sepsis and systemic inflammatory response syndrome. Crit Care Med 2007;35:S584-90
   PubMed Web of Science ®Google Scholar
• Tappy L, Chioléro R. Substrate utilization in sepsis and multiple organ failure. Crit Care Med 2007;35:S531-4
   PubMed Web of Science ®Google Scholar
• Mayer K, Schaefer MB, Seeger W. Fish oil in the critically ill: from experimental to clinical data. Curr Opin Clin Nutr Metab Care 2006;9:140-8
   PubMed Web of Science ®Google Scholar
• Singer P, Shapiro H. Enteral omega-3 in acute respiratory distress syndrome. Curr Opin Clin Nutr Metab Care 2009;12:123-8
   PubMed Web of Science ®Google Scholar
• Pontes-Arruda A, Aragão AM, Albuquerque JD. Effects of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in mechanically ventilated patients with severe sepsis and septic shock. Crit Care Med 2006;34:2325-33
   PubMed Web of Science ®Google Scholar
• Singer P, Shapiro H, Theilla M, Anti-inflammatory properties of omega-3 fatty acids in critical illness: novel mechanisms and an integrative perspective. Intensive Care Med 2008;34:1580-92
   PubMed Web of Science ®Google Scholar
• Terblanche M, Almog Y, Rosenson RS, Statins and sepsis: multiple modifications at multiple levels. Lancet Infect Dis 2007;7:358-68
   PubMed Web of Science ®Google Scholar
• Wanten GJ, Calder PC. Immune modulation by parenteral lipid emulsions. Am J Clin Nutr 2007;85:1171-84
   PubMed Web of Science ®Google Scholar
• Calder PC. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 2006;83:1505S-19S
   PubMed Web of Science ®Google Scholar
• Wendel M, Paul R, Heller AR. Lipoproteins in inflammation and sepsis II. Clinical aspects. Intensive Care Med 2007;33:25-35
   PubMed Web of Science ®Google Scholar
• Mayer K, Fegbeutel C, Hattar K, Omega-3 vs omega-6 lipid emulsions exert differential influence on neutrophils in septic shock patients: impact on plasma fatty acids and lipid mediator generation. Intensive Care Med 2003;29:1472-81
   PubMed Web of Science ®Google Scholar
• Tull SP, Yates CM, Maskrey BH, Omega-3 Fatty acids and inflammation: novel interactions reveal a new step in neutrophil recruitment. PLoS Biol 2009;7:e1000177
   PubMedGoogle Scholar
• Bannenberg GL, Chiang N, Ariel A, Molecular circuits of resolution: formation and actions of resolvins and protectins. J Immunol 2005;174:4345-55
   PubMed Web of Science ®Google Scholar
• Schwab JM, Chiang N, Arita M, Serhan CN. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 2007;447:869-74
   PubMed Web of Science ®Google Scholar
• O'Keefe JH Jr, Abuissa H, Sastre A, Effects of omega-3 fatty acids on resting heart rate, heart rate recovery after exercise, and heart rate variability in men with healed myocardial infarctions and depressed ejection fractions. Am J Cardiol 2006;97:1127-30
   PubMed Web of Science ®Google Scholar
• Das UN. Beneficial effect(s) of n-3 fatty acids in cardiovascular diseases: but, why and how? Prostaglandins Leukot Essent Fatty Acids 2000;63:351-62
   PubMed Web of Science ®Google Scholar
• Borovikova LV, Ivanova S, Zhang M, Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000;405:458-62
   PubMed Web of Science ®Google Scholar
• Nyalala JO, Wang J, Dang A, Hypertriglyceridemia and hypercholesterolemia: effects of drug treatment on fatty acid composition of plasma lipids and membranes. Prostaglandins Leukot Essent Fatty Acids 2008;78:271-80
   PubMed Web of Science ®Google Scholar
• Wang HR, Li JJ, Huang CX, Jiang H. Fluvastatin inhibits the expression of tumor necrosis factor-alpha and activation of nuclear factor-kappa b in human endothelial cells stimulated by C-reactive protein. Clin Chim Acta 2005;353:53-60
   PubMed Web of Science ®Google Scholar
• Huang KC, Chen CW, Chen JC, Lin WW. HMG-CoA reductase inhibitors inhibit inducible nitric oxide synthase gene expression in macrophages. J Biomed Sci 2003;10:396-405
   PubMed Web of Science ®Google Scholar
• Pliquett RU, Cornish KG, Zucker IH. Statin therapy restores sympathovagal balance in experimental heart failure. J Appl Physiol 2003;95:700-4
   PubMed Web of Science ®Google Scholar
• Gao L, Wang W, Li YL, Simvastatin therapy normalizes sympathetic neural control in experimental heart failure: roles of angiotensin II type 1 receptors and NAD(P)H oxidase. Circulation 2005;112:1763-70
   PubMed Web of Science ®Google Scholar
• Pliquett RU, Cornish KG, Peuler JD, Zucker IH. Simvastatin normalizes autonomic neural control in experimental heart failure. Circulation 2003;107:2493-8
   PubMed Web of Science ®Google Scholar
• Liang SL, Liu H, Zhou A. Lovastatin-induced apoptosis in macrophages through the Rac1/Cdc42/JNK pathway. J Immunol 2006;177:651-6
   PubMed Web of Science ®Google Scholar
• Machado FR, Silva E. Coagulation and sepsis. Endocr Metab Immune Disord Drug Targets 2006;6:175-82
   PubMedGoogle Scholar
• Levi M, de Jonge E, van der Poll T. Sepsis and disseminated intravascular coagulation. J Thromb Thrombolysis 2003;16:43-7
   PubMed Web of Science ®Google Scholar
• Undas A, Brozek J, Musial J. Anti-inflammatory and antithrombotic effects of statins in the management of coronary artery disease. Clin Lab 2002;48:287-96
   PubMedGoogle Scholar
• Schafer K, Kaiser K, Konstantinides S. Rosuvastatin exerts favourable effects on thrombosis and neointimal growth in a mouse model of endothelial injury. Thromb Haemost 2005;93:145-2
   PubMed Web of Science ®Google Scholar
• Malinin AI, Ong S, Makarov LM, Platelet inhibition beyond conventional antiplatelet agents: expanding role of angiotensin receptor blockers, statins and selective serotonin reuptake inhibitors. Int J Clin Pract 2006;60:993-1002
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Midei MG, Malinin AI, Absence of interaction between atorvastatin or other statins and clopidogrel: results from the INTERACTION study. Arch Intern Med 2004;164:2051-7
   PubMed Web of Science ®Google Scholar
• Mosheimer BA, Kaneider NC, Feistritzer C, CD40-ligand- dependent induction of COX-2 gene expression in endothelial cells by activated platelets: inhibitory effects of atorvastatin. Blood Coagul Fibrinolysis 2005;16:105-10
   PubMed Web of Science ®Google Scholar
• Antoniades C, Bakogiannis C, Tousoulis D, The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol 2009;54:669-77
   PubMed Web of Science ®Google Scholar
• Puccetti L, Pasqui AL, Pastorelli M, Time-dependent effects of statins on platelet function in hypercholesterolaemia. Eur J Clin Invest 2002;32:901-8
   PubMed Web of Science ®Google Scholar
• Dyerberg J, Bang HO. Haemostatic function and platelet polyunsaturated fatty acids in Eskimos. Lancet 1979;2:433-5
   PubMed Web of Science ®Google Scholar
• Guillot N, Caillet E, Laville M, Increasing intakes of the long-chain omega-3 docosahexaenoic acid: effects on platelet functions and redox status in healthy men. FASEB J 2009;23:2909-16
   PubMed Web of Science ®Google Scholar
• Del Turco S, Basta G, Lazzerini G, Effect of the administration of n-3 polyunsaturated fatty acids on circulating levels of microparticles in patients with a previous myocardial infarction. Haematologica 2008;93:892-9
   PubMed Web of Science ®Google Scholar
• Hartweg J, Farmer AJ, Holman RR, Neil HA. Meta-analysis of the effects of n-3 polyunsaturated fatty acids on haematological and thrombogenic factors in type 2 diabetes. Diabetologia 2007;50:250-8
   PubMed Web of Science ®Google Scholar
• Lee KW, Lip GY. Effects of lifestyle on hemostasis, fibrinolysis, and platelet reactivity: a systematic review. Arch Intern Med 2003;163:2368-92
   PubMed Web of Science ®Google Scholar
• Nordoy A, Bonaa KH, Sandset PM, Effect of omega-3 fatty acids and simvastatin on hemostatic risk factors and postprandial hyperlipemia in patients with combined hyperlipemia. Arterioscler Thromb Vasc Biol 2000;20:259-65
   PubMed Web of Science ®Google Scholar
• Nordøy A, Svensson B, Hansen JB. Atorvastatin and omega-3 fatty acids protect against activation of the coagulation system in patients with combined hyperlipemia. J Thromb Haemost 2003;1:690-7
   PubMed Web of Science ®Google Scholar
• Barter P, Ginsberg HN. Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia. Am J Cardiol 2008;102:1040-5
   PubMed Web of Science ®Google Scholar
• McKenney JM, Sica D. Prescription omega-3 fatty acids for the treatment of hypertriglyceridemia. Am J Health Syst Pharm 2007;64:595-605
   PubMed Web of Science ®Google Scholar
• Davidson MH, Stein EA, Bays HE, Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebcontrolled study. Clin Ther 2007;29:1354-67
   PubMed Web of Science ®Google Scholar
• Kruger PS, Freir NM, Venkatesh B, A preliminary study of atorvastatin plasma concentrations in critically ill patients with sepsis. Intensive Care Med 2009;35:717-21
   PubMed Web of Science ®Google Scholar
• McKenney JM, Swearingen D, Di Spirito M, Study of the pharmacokinetic interaction between simvastatin and prescription omega-3-acid ethyl esters. J Clin Pharmacol 2006;46:785-91
   PubMed Web of Science ®Google Scholar
• Di Spirito M, Morelli G, Doyle RT, Effect of omega-3-acid ethyl esters on steady-state plasma pharmacokinetics of atorvastatin in healthy adults. Expert Opin Pharmacother 2008;9:2939-45
   PubMed Web of Science ®Google Scholar
• Iso H, Rexrode KM, Stampfer MJ, Intake of fish and omega-3 fatty acids and risk of stroke in women. JAMA 2001;285:304-12
   PubMed Web of Science ®Google Scholar
• He K, Rimm EB, Merchant A, Fish consumption and risk of stroke in men. JAMA 2002;288:3130-6
   Google Scholar
• Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. Omega-3 fatty acids: how can they be used in secondary prevention? Curr Atheroscler Rep 2008;10:510-7
   PubMed Web of Science ®Google Scholar
• Merx MW, Liehn EA, Graf J, Statin treatment after onset of sepsis in a murine model improves survival. Circulation 2005;112:117-24
   PubMed Web of Science ®Google Scholar
• McGown CC, Brown NJ, Hellewell PG, Beneficial microvascular and anti-inflammatory effects of pravastatin during sepsis involve nitric oxide synthase III. Br J Anaesth 2010;104:183-90
   PubMed Web of Science ®Google Scholar
• Relja B, Lehnert M, Seyboth K, Simvastatin reduces mortality and hepatic injury after hemorrhage/resuscitation in rats. Shock 2009. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Subramani J, Kathirvel K, Leo MD, Atorvastatin restores the impaired vascular endothelium-dependent relaxations mediated by nitric oxide and endothelium-derived hyperpolarizing factors but not hypotension in sepsis. J Cardiovasc Pharmacol 2009;54:526-34
   PubMed Web of Science ®Google Scholar
• Gao F, Linhartova L, Johnston AM, Thickett DR. (2008) Statins and sepsis. Br J Anaesth 2008;100:288-98
   PubMed Web of Science ®Google Scholar
• The STATInS trial: Statins in Sepsis Study 2007 ACTRN 12607000028404. Available from: http://www.anzctr.org.au/trial_view.aspx?ID=81692
   Google Scholar
• The CAS trial: continued use of Atorvastatin in sepsis 2006 ACTRN12605000756628. Available from: http://www.anzctr.org.au/trial_view.aspx?ID=886
   Google Scholar
• Wenger NK, Lewis SJ, Herrington DM, Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann Intern Med 2007;147:1-9
   PubMed Web of Science ®Google Scholar
• Davidson MH, Robinson JG. Safety of aggressive lipid management. J Am Coll Cardiol 2007;49:1753-62
   PubMed Web of Science ®Google Scholar